Epithalon vs Pinealon
Epithalon and Pinealon are both short synthetic peptides from the same Russian research programme on pineal-gland peptides, led by Vladimir Khavinson in St Petersburg 1,5,7. Epithalon (Ala-Glu-Asp-Gly) was synthesised from the amino-acid content of a bovine pineal extract and in human cell culture induced telomerase activity 1,3. Pinealon (Glu-Asp-Arg, also called the EDR peptide) was studied for effects on reactive oxygen species in nerve and other cells 5,7. The FDA reviewed Epithalon for compounding in July 2026 and proposed it not be listed; Pinealon does not appear in the FDA's compounding nomination categories at all 1,11.
Side by side
| Field | Epithalon | Pinealon |
|---|---|---|
| Class | Synthetic tetrapeptide (Ala-Glu-Asp-Gly) 1 | Synthetic tripeptide (Glu-Asp-Arg), also called the EDR peptide 5,7 |
| Origin and structure | Synthesised from the amino-acid composition of epithalamin, a bovine pineal extract; the FDA treats the two as different substances 1,4 | Designed short peptide from the same Russian pineal-peptide programme; no natural source is described in the sources reviewed 5,7 |
| Proposed mechanism | Induced telomerase expression and telomere elongation in human fetal fibroblasts 3; reported to raise melatonin levels by an unknown mechanism 1 | In cerebellar granule cells, neutrophils and PC12 cells, limited reactive oxygen species accumulation and altered ERK1/2 activation and the cell cycle 5; proposed to bind DNA sequences and act epigenetically 7,9 |
| Half-life | No pharmacokinetic data found by the FDA 1 | Not located in the sources reviewed |
| Highest human trial phase | No completed trials identified; one early phase 1 multi-agent ageing study (NCT07888595) matched a registry search 12 | No registered trials; one small Russian study of 32 patients reported biological-age measures with two peptides 10,13 |
| FDA status | Not FDA-approved; the FDA proposed it not be added to the 503A compounding bulks list (PCAC, 24 July 2026) 1,2; previously listed among withdrawn category 2 nominations 14 | Not FDA-approved; no Drugs@FDA record (queried 24 October 2026) 15; not in any 503A nomination category as updated 14 May 2026 11 |
| Published human outcomes | The FDA found no studies in people with insomnia; human reports concern melatonin levels in older people, mostly with epithalamin 1 | One Russian-language study in 32 people aged 41 to 83 with chronic multimorbidity reported changes in biological-age markers, with a second peptide showing larger changes than Pinealon 10 |
| Safety signals | FDA found no human safety data and flagged a theoretical cancer concern because it activates telomerase 1 | The 32-person Russian study reported prooxidant activity by chemiluminescence and lower blood CD34+ cell markers 10 |
| WADA status | Not named on the 2026 Prohibited List; section S0 covers substances with no governmental approval for human use 16 | Not named on the 2026 Prohibited List; section S0 covers substances with no governmental approval for human use 16 |
| Who funded the evidence | Largely the St Petersburg Institute of Bioregulation and Gerontology and the Russian Academy of Medical Sciences 1,3 | The same St Petersburg research network, with collaborating Russian institutes 5,7,8 |
Epithalon: what the data says
Epithalon was synthesised from the amino-acid composition of epithalamin, a bovine pineal extract, and most of its literature comes from the group that developed it 1,4. In human fetal fibroblast cultures (cell data), it induced the catalytic subunit of telomerase, telomerase activity and telomere elongation 3. In fluorescence studies in HeLa cells (cell data), labelled Epithalon entered the nucleus and bound preferentially to DNA sequences containing CNG motifs 9. In organotypic rat pineal cultures, it stimulated the proliferation marker Ki-67 and the transcription factor CGRP 8.
The FDA's 2026 review found no studies of epitalon in people with insomnia, no pharmacokinetic data and no human safety data, and judged mouse toxicology too limited to inform cancer risk 1.
Pinealon: what the data says
Pinealon (Glu-Asp-Arg) was studied mainly in cells. In cerebellar granule cells, neutrophils and PC12 cells (cell data), it limited reactive oxygen species accumulation and necrotic cell death, with delayed ERK1/2 activation and cell-cycle changes; the authors proposed direct interaction with the genome 5. In rats whose mothers were given a methionine load during pregnancy (animal data), offspring given Pinealon showed changes in spatial-orientation and learning measures and lower reactive oxygen species in isolated cerebellar neurons 6. A 2020 review by the same group summarises reported effects on signalling pathways and antioxidant-enzyme synthesis 7.
Human evidence is a single small Russian-language study in 32 people aged 41 to 83 with chronic multimorbidity and an organic brain syndrome in remission, which reported changes in biological-age indicators and, alongside them, prooxidant activity on chemiluminescence and lower CD34+ cell markers in blood 10. No registered trials were found 13.
Key research differences
- Structure: Epithalon is a four-amino-acid peptide 1, while Pinealon is a three-amino-acid peptide 5.
- Proposed mechanism: Epithalon work centres on telomerase and melatonin 1,3, whereas Pinealon work centres on limiting reactive oxygen species and on proposed DNA binding 5,7.
- Human data: Epithalon human reports concern melatonin levels, often with the related extract epithalamin 1; Pinealon has one small Russian study of biological-age markers 10.
- Regulatory attention: the FDA formally reviewed Epithalon for compounding in 2026 1,2, while Pinealon does not appear in any 503A nomination category 11.
- Reported redox direction: cell studies describe Pinealon as limiting reactive oxygen species 5, yet the 32-person human study reported prooxidant activity on chemiluminescence 10.
Where the evidence is limited
No study has compared Epithalon and Pinealon in people. Both come from one research network, which limits independent replication, and several papers test them side by side only in cell cultures 7,8,9. The single human Pinealon study was small, Russian-language, used composite biological-age measures and combined the peptide with another, so its findings cannot be attributed to Pinealon alone 10. For Epithalon, the FDA found no clinical insomnia data, no pharmacokinetics and no human safety data 1.
Frequently asked questions
Are Epithalon and Pinealon related?
Is Pinealon the same as the EDR peptide?
Has either been tested in a registered clinical trial?
References
- FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate) FDA. 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of 08/06/2026) FDA. 2026
- Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells Bulletin of Experimental Biology and Medicine. 2003
- Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties International Journal of Molecular Sciences. 2025
- Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes Rejuvenation Research. 2011
- Pinealon protects the rat offspring from prenatal hyperhomocysteinemia International Journal of Clinical and Experimental Medicine. 2012
- EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease Molecules. 2020
- Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture Bulletin of Experimental Biology and Medicine. 2011
- Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA Biochemistry (Moscow). 2011
- Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission (in Russian) Advances in Gerontology. 2015
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
- ClinicalTrials.gov registry search: epitalon (one early phase 1 multi-agent study, NCT07888595, returned; searched 24 October 2026) ClinicalTrials.gov. 2026
- ClinicalTrials.gov registry search: pinealon (no registered studies returned, searched 24 October 2026) ClinicalTrials.gov. 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) FDA (Human Drug Compounding). 2026
- Drugs@FDA via openFDA: query for pinealon (no matching application, queried 24 October 2026) openFDA. 2026
- Prohibited List (2026 List, in force 1 January 2026) World Anti-Doping Agency. 2026
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page compares published research and is not medical advice or a recommendation.

